DELCO Today on MSN11d
Iovance Biotherapeutics Likely to Add Hundreds of New Jobs At Philadelphia Navy YardAs part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new ...
Iovance Biotherapeutics shares declined after its primary cancer treatment fell short of revenue expectations. The stock fell 19% to $4.28 on Friday, at one point dropping to a 52-week low of $3.62.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback